Search

Home > Lung Cancer Considered > FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC
Podcast: Lung Cancer Considered
Episode:

FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC
Category: Science & Medicine
Duration: 00:33:15
Publish Date: 2025-05-27 13:00:26
Description: In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.
Total Play: 0